Quest for Growth has announced that Wilex AG, its portfolio company, has successfully placed new shares in its IPO on the Frankfurt exchange. Wilex is a biopharmaceutical company based in Munich, which was founded in 1997 by a team of physicians and oncologists from the technical university of Munich. The company focuses on the development of new cancer therapies based on antibodies and small molecules which target the prevention of growth, spread and metastasis of malignant tumours and the destruction of malignant tumours in the body.
Allßequitz backing for the heart pump developer also comes from Beteiligungsmanagement Thüringen
Deal is VC's sixth investment from its Deep-tech Fund
GP is currently investing via its Partech Entrepreneur Fund III and Paris Saclay Seed Fund
Fund targets European companies with expansion and growth plans in the Chinese market